Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study-Reference-Cited by-同舟云学术

Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study

Published:2019-01-09 Issue:1 Volume:20 Page:
ISSN:1745-6215
Container-title:Trials
language:en
Short-container-title:Trials

Author:

Chen Yiyi,Cao Xiaomin,Zang Wensi,Tan Shanyong,Ou Chun-quan,Shen Xiaoyan,Gao Tianming,Zhao Lianxu

Funder

National Natural Science Foundation of China

the Program for Changjiang Scholars and Innovative Research Team in University

the Guangzhou Science and Technology Project

the Natural Science Foundation of Guangdong

Clinical Research Startup Program of Southern Medical University by High-level University Construction Funding of Guangdong Provincial Department of Education

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Medicine (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1186/s13063-018-3115-4.pdf

Reference49 articles.

1. Atun R. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):721–2.

2. Gu L, Xie J, Long J, et al. Epidemiology of major depressive disorder in mainland china: a systematic review. PLoS One. 2013;8(6):e65356.

3. Schildkraut J. The catecholamine hypothesis of affective disorders a review of supporting evidence. Am J Psychiatry. 1965;122(5):509–22.

4. Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14(5):334–85.

5. Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med. 2005;143:415–26.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A refined formula derived from Jiawei-Xiaoyao pill exerts rapid antidepressant-like effects in LPS-induced depression by reducing neuroinflammation and restoring neuroplasticity signaling;Journal of Ethnopharmacology;2024-12

2. The neurobiological mechanisms and therapeutic prospect of extracellular ATP in depression;CNS Neuroscience & Therapeutics;2024-02

3. The ATP-dependent Pathways and Human Diseases;Current Medicinal Chemistry;2023-04

4. Sinisan alleviates depression-like behaviors by regulating mitochondrial function and synaptic plasticity in maternal separation rats;Phytomedicine;2022-11

5. Synergistic effects of two naturally occurring iridoids in eliciting a rapid antidepressant action by up‐regulating hippocampal PACAP signalling;British Journal of Pharmacology;2022-04-22